Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18“59 at Increased Risk for RSV Disease

The FDA has approved Moderna's mRESVIA RSV vaccine for adults aged 18-59 at increased risk, expanding its prior approval for those 60 and older; this decision was supported by Phase 3 trial data demonstrating non-inferior immunogenicity compared to older adults, with comparable neutralizing antibody levels observed across age subgroups. Moderna intends to make mRESVIA available for both younger and older adults in the U.S. for the 2025-2026 respiratory virus season, addressing a significant disease burden in adults with chronic conditions.

Analysis

Moderna, Inc. (NASDAQ:MRNA) has secured a significant U.S. FDA approval broadening the indication for its mRESVIA RSV vaccine to include individuals aged 18-59 at increased risk for severe disease, an expansion from the initial approval for adults aged 60 and older. This regulatory milestone, announced June 12, 2025, is supported by Phase 3 study (NCT06067230) results which demonstrated non-inferior immunogenicity and comparable neutralizing antibody levels against both RSV-A and RSV-B subtypes when compared to the older adult cohort. The expanded approval taps into a substantial market, as the article notes over one-third of U.S. adults aged 18-59 possess at least one underlying condition elevating their RSV risk, with disease burden and hospitalization rates in this demographic reportedly comparable to, or even exceeding, those in older adults. Moderna's plan to make mRESVIA available for both approved adult populations in the U.S. for the 2025-2026 respiratory virus season positions the product for potential market share capture and revenue growth, further diversifying its portfolio beyond COVID-19 vaccines and reinforcing the utility of its mRNA platform. The vaccine was reported as generally well-tolerated, with the most commonly reported solicited adverse reactions being injection site pain, fatigue, headache, myalgia, and arthralgia.

Key Decisions for Investors

• Investors should evaluate the incremental revenue potential for Moderna stemming from mRESVIA's expanded label, particularly given the identified disease burden in the 18-59 at-risk demographic and the product's planned availability for the 2025-2026 season.
• Consideration should be given to Moderna's commercial execution strategy for mRESVIA in a competitive RSV landscape and its ability to effectively penetrate this newly approved, younger adult market segment.
• This regulatory success for mRESVIA further substantiates the versatility of Moderna's mRNA technology beyond COVID-19, which may positively influence the risk assessment and valuation of its broader pipeline candidates.